U.S. flag

An official website of the United States government

NM_058216.3(RAD51C):c.109G>A (p.Glu37Lys) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jul 5, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002450610.2

Allele description [Variation Report for NM_058216.3(RAD51C):c.109G>A (p.Glu37Lys)]

NM_058216.3(RAD51C):c.109G>A (p.Glu37Lys)

Gene:
RAD51C:RAD51 paralog C [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q22
Genomic location:
Preferred name:
NM_058216.3(RAD51C):c.109G>A (p.Glu37Lys)
HGVS:
  • NC_000017.11:g.58692752G>A
  • NG_023199.1:g.5151G>A
  • NG_047169.1:g.4328C>T
  • NM_002876.4:c.109G>A
  • NM_058216.3:c.109G>AMANE SELECT
  • NM_058217.1:c.109G>A
  • NP_002867.1:p.Glu37Lys
  • NP_478123.1:p.Glu37Lys
  • NP_478123.1:p.Glu37Lys
  • NP_478124.1:p.Glu37Lys
  • LRG_314t1:c.109G>A
  • LRG_314:g.5151G>A
  • LRG_314p1:p.Glu37Lys
  • NC_000017.10:g.56770113G>A
  • NM_058216.1:c.109G>A
  • NR_103872.2:n.151G>A
Protein change:
E37K
Molecular consequence:
  • NM_002876.4:c.109G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_058216.3:c.109G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_058217.1:c.109G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_103872.2:n.151G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV002734577Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Uncertain significance
(Jul 5, 2022) 		germlineclinical testing

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV002734577.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The p.E37K variant (also known as c.109G>A), located in coding exon 1 of the RAD51C gene, results from a G to A substitution at nucleotide position 109. The glutamic acid at codon 37 is replaced by lysine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024